SEC Company Response from Salarius Pharmaceuticals, Inc. (DCOY) (CIK 0001615219) (DCOY) — Feb 5, 2020
Salarius Pharmaceuticals, Inc. (DCOY) (CIK 0001615219)
Date: Feb. 5, 2020 · CIK: 0001615219 · Accession: 0001193125-20-025393
AI Filing Summary & Sentiment
File numbers found in text: 333-235879
Letter
SALARIUS PHARMACEUTICALS, INC.
2450 Holcombe Blvd., Suite J-608
Houston, TX 77021
February 5, 2020
VIA FACSIMILE AND EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C.
Re: Salarius Pharmaceuticals, Inc. - Registration Statement – Form S-1
File No. 333-235879
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended Salarius Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced registration statement on Form S-1 (File No. 333-235879) (the “Registration Statement”) be declared effective on February 6, 2020, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Davina K. Kaile and Julie Park of Pillsbury Winthrop Shaw Pittman LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Davina K. Kaile of Pillsbury Winthrop Shaw Pittman LLP, counsel to the Registrant, at (650) 233-4564, or in her absence, Julie Park at (650) 233-4067.
[Signature Page Follows]
Sincerely,
SALARIUS PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP SALARIUS PHARMACEUTICALS, INC. 2450 Holcombe Blvd., Suite J-608 Houston, TX 77021 February 5, 2020 VIA FACSIMILE AND EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Salarius Pharmaceuticals, Inc. - Registration Statement – Form S-1 File No. 333-235879 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended Salarius Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced registration statement on Form S-1 (File No. 333-235879) (the “Registration Statement”) be declared effective on February 6, 2020, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Davina K. Kaile and Julie Park of Pillsbury Winthrop Shaw Pittman LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Davina K. Kaile of Pillsbury Winthrop Shaw Pittman LLP, counsel to the Registrant, at (650) 233-4564, or in her absence, Julie Park at (650) 233-4067. [Signature Page Follows] Sincerely, SALARIUS PHARMACEUTICALS, INC. By: /s/ David J. Arthur David J. Arthur Chief Executive Officer cc: Davina K. Kaile, Esq.